Tokyo, Japan \u2014 May 14, 2026\u202f\u2014<\/p>\n\n\n\n
CellFiber Co., Ltd., a biotech company pioneering next-generation cell culture technology, has announced that its partner, Locus Cell Co., Ltd. (Locus Cell), has established a commercial-scale, manufacturing process for umbilical cord-derived mesenchymal stromal cells using CellFiber\u00ae technology.<\/p>\n\n\n\n
The process has now been further upgraded to automated production with the official inauguration of Locus Cell’s Zhubei automated smart factory. This milestone demonstrates the viability of CellFiber\u00ae technology as a scalable manufacturing platform for cell-based medicines.<\/p>\n\n\n\n
CellFiber\u00ae is CellFiber\u2019s proprietary next-generation cell culture platform designed to enable the efficient production of high-quality cells. The technology is based on an encapsulation method that forms tube-like alginate hydrogel structures, which protect cells during culture. Compared with conventional methods, cells cultured using CellFiber\u00ae technology show improved preservation of cell function,viability, and enhanced cell uniformity. With the inauguration of the Zhubei automated smart factory\u2014the largest smart facility of its kind in Asia\u2014the manufacturing process using CellFiber\u00ae has been integrated into an automated production line.<\/p>\n\n\n\n
CellFiber will continue to work with Locus Cell to advance the deployment of CellFiber\u00ae technology in the Asia Pacific market and contribute to the widespread adoption of regenerative medicine.<\/p>\n\n\n\n
About Locus Cell Co., Ltd.<\/strong> About CellFiber Co., Ltd.<\/strong> \uff1cCompany Profile\uff1e<\/strong> MEDIA CONTACT <\/p>\n","protected":false},"excerpt":{"rendered":" Tokyo, Japan \u2014 May 14, 2026\u202f\u2014 CellFiber Co., Ltd., a biotech company pioneering next-generation cell culture technology, has announced that its partner, Locus Cell Co., Ltd. (Locus Cell), has established a commercial-scale, manufacturing process for umbilical cord-derived mesenchymal stromal cells using CellFiber\u00ae technology. The process has now been further upgraded to automated production with the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-641","post","type-post","status-publish","format-standard","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/posts\/641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/comments?post=641"}],"version-history":[{"count":2,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/posts\/641\/revisions"}],"predecessor-version":[{"id":655,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/posts\/641\/revisions\/655"}],"wp:attachment":[{"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/media?parent=641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/categories?post=641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cellfiber.jp\/en\/wp-json\/wp\/v2\/tags?post=641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Locus Cell Co., Ltd. is a biotechnology company headquartered in Hsinchu, Taiwan. As a CDMO (Contract Development and Manufacturing Organization) specializing in GMP-compliant cell manufacturing, Locus Cell drives large-scale commercial manufacturing in the fields of regenerative medicine and cell therapy. The company operates the Zhubei automated smart factory, the largest facility of its kind in Asia, and actively pursues strategic partnerships with biopharmaceutical companies in Japan, Europe, and the United States.<\/p>\n\n\n\n
CellFiber is a Tokyo-based biotechnology company built on proprietary 3D cell culture technology. Guided by the vision of \u201ccell culture reimagined,\u201d the company is advancing the use of innovative cell culture platforms beyond academic research and supporting their global adoption across the regenerative medicine ecosystem. Through its proprietary closed, automated fiber-encapsulation system, CellFiber enables high-density, reproducible, and controlled cell expansion at scale. The company is focused on redefining how therapeutic cells are manufactured by providing scalable, efficient, and GMP-aligned solutions that support developers from early R&D through clinical production.<\/p>\n\n\n\n
Company name: CellFiber Co., Ltd.
Head office: MSC Fukagawa Building No. 2, Room 105, 2-9-8 Saga, Koto-ku, Tokyo 135-0031, Japan
Representative: Representative Director, CEO Kazuchika Furuishi
Date of establishment: April 1, 2015
Business Description: Research, development, production, and sales of biomaterials and soft materials containing living cells (MAP)
URL: https:\/\/cellfiber.jp\/en\/<\/a><\/p>\n\n\n\n
Email: cellfiber@storieson.co.jp<\/p>\n\n\n\n